Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics

BACKGROUND: Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and functional remission in patients with schizophrenia. This post hoc analysis aimed to identify factors associated with improved clinical outcomes in patients switching to PP1M (75–150 mg eq.). METHODS: The improved pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Nan, Feng, Yu, Lu, Huafei, Cai, Shang Li, Zhuo, Jianmin, Si, Tianmei, Zhang, Lili
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868613/
https://www.ncbi.nlm.nih.gov/pubmed/29606876
http://dx.doi.org/10.2147/NDT.S158353

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868613/
https://www.ncbi.nlm.nih.gov/pubmed/29606876
http://dx.doi.org/10.2147/NDT.S158353

Ejemplares similares